Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

NYSE:PACS - New York Stock Exchange, Inc. - US69380Q1076 - Common Stock - Currency: USD

13  -0.07 (-0.54%)

After market: 13 0 (0%)

Fundamental Rating

3

Taking everything into account, PACS scores 3 out of 10 in our fundamental rating. PACS was compared to 107 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. PACS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PACS was profitable.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

PACS's Return On Assets of 2.90% is fine compared to the rest of the industry. PACS outperforms 67.59% of its industry peers.
PACS has a Return On Equity of 19.73%. This is amongst the best in the industry. PACS outperforms 90.74% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.38%, PACS is in line with its industry, outperforming 53.70% of the companies in the same industry.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

With a decent Profit Margin value of 3.63%, PACS is doing good in the industry, outperforming 76.85% of the companies in the same industry.
With a decent Operating Margin value of 6.68%, PACS is doing good in the industry, outperforming 73.15% of the companies in the same industry.
With a Gross Margin value of 21.33%, PACS perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PACS has about the same amout of shares outstanding than it did 1 year ago.
PACS has a worse debt/assets ratio than last year.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.48, we must say that PACS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.48, PACS is not doing good in the industry: 60.19% of the companies in the same industry are doing better.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
PACS's Debt to Equity ratio of 0.90 is on the low side compared to the rest of the industry. PACS is outperformed by 63.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.48
ROIC/WACC0.52
WACC8.37%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PACS has a Current Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.71, PACS is doing good in the industry, outperforming 62.04% of the companies in the same industry.
PACS has a Quick Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.71, PACS is in the better half of the industry, outperforming 65.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PACS have decreased strongly by -25.00% in the last year.
The Revenue has grown by 28.47% in the past year. This is a very strong growth!
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

PACS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.14% yearly.
Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 19.39% on average per year.
EPS Next Y55.8%
EPS Next 2Y57.15%
EPS Next 3Y43.14%
EPS Next 5YN/A
Revenue Next Year30.45%
Revenue Next 2Y23.44%
Revenue Next 3Y19.39%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 17.11 indicates a rather expensive valuation of PACS.
Compared to the rest of the industry, the Price/Earnings ratio of PACS indicates a somewhat cheap valuation: PACS is cheaper than 73.15% of the companies listed in the same industry.
PACS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.35.
Based on the Price/Forward Earnings ratio of 6.89, the valuation of PACS can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PACS indicates a rather cheap valuation: PACS is cheaper than 96.30% of the companies listed in the same industry.
PACS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE 17.11
Fwd PE 6.89
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PACS is valued a bit cheaper than the industry average as 73.15% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.61
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 43.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y57.15%
EPS Next 3Y43.14%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (3/7/2025, 8:04:01 PM)

After market: 13 0 (0%)

13

-0.07 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners32.33%
Inst Owner Change-4.06%
Ins Owners72.29%
Ins Owner Change0%
Market Cap2.02B
Analysts83.08
Price Target33.08 (154.46%)
Short Float %6.35%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-19.22%
EPS NQ rev (1m)15.93%
EPS NQ rev (3m)15.93%
EPS NY rev (1m)11.11%
EPS NY rev (3m)11.11%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)0.4%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)1.1%
Valuation
Industry RankSector Rank
PE 17.11
Fwd PE 6.89
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 3.98
EV/EBITDA 10.61
EPS(TTM)0.76
EY5.85%
EPS(NY)1.89
Fwd EY14.51%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.31
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.48
F-ScoreN/A
WACC8.37%
ROIC/WACC0.52
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y55.8%
EPS Next 2Y57.15%
EPS Next 3Y43.14%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year30.45%
Revenue Next 2Y23.44%
Revenue Next 3Y19.39%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.84%
EBIT Next 3Y38.44%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A